Immunomedics Inc. (IMMU) Well Positioned on the Back of Trodelvy Data - Cowen
Tweet Send to a Friend
Cowen analyst Phil Nadeau reiterated an Outperform rating and $45.00 price target on Immunomedics (NASDAQ: IMMU) citing a PH. III ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
